Literature DB >> 9357099

Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.

P Dalén1, C Frengell, M L Dahl, F Sjöqvist.   

Abstract

The authors describe a 33-year-old woman who experienced severe pain in the epigastrium after codeine intake. This side-effect is consistent with that of morphine. Later, the patient was phenotyped and genotyped as an ultrarapid metabolizer with high capacity to metabolize codeine to morphine.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9357099     DOI： 10.1097/00007691-199710000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  30 in total

1.  Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Authors:  Takeshi Shiiki; Yukiya Hashimoto; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 2.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 5.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 6.  Genetic variability of pain perception and treatment--clinical pharmacological implications.

Authors:  Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2011-02-23       Impact factor: 2.953

7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

Review 10.  Genes associated with addiction: alcoholism, opiate, and cocaine addiction.

Authors:  Mary Jeanne Kreek; David A Nielsen; K Steven LaForge
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.